An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus
Latest Information Update: 16 Oct 2021
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational
- Sponsors Cara Therapeutics
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2019 According to a Cara Therapeutics media release, this trial is expected to support worldwide registration filings of KORSUVA Injection.